Professor Andrew Spencer and his team have established a large prospective registry of newly-diagnosed patients with myeloma, plasmacytoma, plasma cell leukaemia and MGUS. The Myeloma and Related Diseases Registry (MRDR) is providing rich real world data to help inform clinical practice. In this podcast, we talk to Professor Spencer about how the findings from the registry are helping clinical decision making.

This podcast was sponsored by Janssen. The content is based on published studies and the opinions of independent experts. The views expressed are not necessarily those of Janssen.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au/velcade_PI).